Abivax SA ( (FR:ABVX) ) has issued an announcement.
Abivax has disclosed the total number of shares and voting rights as of February 28, 2025, with 63,383,293 shares and 71,083,363 exercisable voting rights. This information is crucial for stakeholders to understand the company’s shareholding structure and voting power distribution, which can impact decision-making and corporate governance.
More about Abivax SA
Abivax is a clinical-stage biotechnology company focused on developing therapeutic treatments that exploit the body’s natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax’s flagship drug candidate, obefazimod (ABX464), is in phase 3 clinical development for the treatment of moderately to severely active ulcerative colitis.
YTD Price Performance: -3.25%
Average Trading Volume: 951
Technical Sentiment Signal: Buy
Current Market Cap: €425.2M
Find detailed analytics on ABVX stock on TipRanks’ Stock Analysis page.